Oncology Featured Articles

  1. Toxicometabolomics For Compound Attrition To Reduce Late Stage Failures Due To Safety 4/10/2013

    Many ’omics’ technologies have now become the primary way of discovering new biomarkers, and validation of these biomarkers is a relatively new and evolving concept. By Michael V. Milburn, John A. Ryals, and Lining Guo

  2. Growing To Meet The Needs Of Big Pharma: Acquisitions Help BioClinica Increase Profits by 20% 3/26/2013

    Recent acquisitions have convinced Mark Weinstein, CEO of BioClinica, that his company is ready to work with the largest of pharmaceutical companies, be they CRO or drug sponsor. Bio-Imaging, which officially became BioClinica in 2009 following a major merger, is currently running over 400 imaging studies with over 200 clients. Weinstein notes a series of well-planned steps were required to get them to this position.

  3. Integrative Biology: At The Tipping Point 10/7/2011

    I recently met Gustavo Salem, VP and general manager of the Biological Systems Division at Agilent Technologies. Salem believes integrative biology is at a tipping point for producing major breakthroughs in the drug development. By Rob Wright, Chief Editor, Life Science Leader magazine

  4. Breast Cancer Vaccine - Holds Promise For Several Players 9/15/2011
    I came across a headline in one of my news feeds announcing the FDA clearing the way for RXi Pharmaceuticals to move forward with plans for final-stage testing of a cancer vaccine. This might not seem like big news.